[go: up one dir, main page]

MXPA05012637A - Tableta de liberacion modificada del clorhidrato de bupropion. - Google Patents

Tableta de liberacion modificada del clorhidrato de bupropion.

Info

Publication number
MXPA05012637A
MXPA05012637A MXPA05012637A MXPA05012637A MXPA05012637A MX PA05012637 A MXPA05012637 A MX PA05012637A MX PA05012637 A MXPA05012637 A MX PA05012637A MX PA05012637 A MXPA05012637 A MX PA05012637A MX PA05012637 A MXPA05012637 A MX PA05012637A
Authority
MX
Mexico
Prior art keywords
modified
release tablet
bupropion hydrochloride
core
releasing coat
Prior art date
Application number
MXPA05012637A
Other languages
English (en)
Inventor
Fang Zhou
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34192557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05012637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of MXPA05012637A publication Critical patent/MXPA05012637A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una tableta de liberacion modificada de clorhidrato de bupropion que comprende (1) un nucleo que comprende una cantidad efectiva de clorhidrato de bupropion, un aglutinante, un lubricante y (ii) un recubrimiento para controlar la liberacion que rodea el nucleo y (iii) una barrera contra la humedad que rodea el recubrimiento para controlar la liberacion, en donde la tableta de liberacion modificada es bioequivalente a las tabletas de Wellbutrin(r) o de Zyban(r)/Wellbutrin(r)SR.
MXPA05012637A 2003-08-08 2003-08-08 Tableta de liberacion modificada del clorhidrato de bupropion. MXPA05012637A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/024700 WO2005016318A1 (en) 2003-08-08 2003-08-08 Modified-release tablet of bupropion hydrochloride

Publications (1)

Publication Number Publication Date
MXPA05012637A true MXPA05012637A (es) 2006-02-24

Family

ID=34192557

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012637A MXPA05012637A (es) 2003-08-08 2003-08-08 Tableta de liberacion modificada del clorhidrato de bupropion.

Country Status (29)

Country Link
US (2) US20050238718A1 (es)
EP (1) EP1575565B1 (es)
JP (1) JP2007521231A (es)
KR (1) KR101087464B1 (es)
CN (1) CN1819821B (es)
AP (1) AP1899A (es)
AT (1) ATE454138T1 (es)
AU (1) AU2003264002B2 (es)
BR (1) BRPI0318456B8 (es)
CA (1) CA2524300C (es)
CR (1) CR8056A (es)
CY (1) CY1109955T1 (es)
DE (1) DE60330909D1 (es)
DK (1) DK1575565T3 (es)
EA (1) EA013737B1 (es)
ES (1) ES2336913T3 (es)
HR (1) HRP20050625B1 (es)
IL (1) IL171870A (es)
IS (1) IS2779B (es)
ME (2) MEP3608A (es)
MX (1) MXPA05012637A (es)
NO (2) NO335271B1 (es)
NZ (1) NZ544281A (es)
PL (1) PL196544B1 (es)
PT (1) PT1575565E (es)
RS (2) RS51934B (es)
SI (1) SI1575565T1 (es)
TN (1) TNSN06016A1 (es)
WO (1) WO2005016318A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
BRPI0410805A (pt) 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
PL2801354T3 (pl) 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
EP1909973B1 (en) 2005-07-15 2018-08-22 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
BRPI0715959A2 (pt) * 2006-08-21 2013-07-30 Jubilant Organosys Ltd composiÇço farmacÊutica de liberaÇço modificada de cloridrato de bupropion
WO2008052000A2 (en) 2006-10-23 2008-05-02 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
EP2170418B1 (en) * 2007-05-25 2016-03-16 Micell Technologies, Inc. Polymer films for medical device coating
US20100203128A1 (en) * 2007-08-07 2010-08-12 Biovail Laboratories International Srl Bupropion hydrobromide and therapeutic applications
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
MX2010011485A (es) 2008-04-17 2011-03-01 Micell Technologies Inc Stents que contienen capas bioadsorbibles.
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
RU2743637C2 (ru) 2009-01-09 2021-02-20 Фвп Ип Апс Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
EP2413847A4 (en) 2009-04-01 2013-11-27 Micell Technologies Inc COATED STENTS
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
CA2905419C (en) 2013-03-12 2020-04-28 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2912387C (en) 2013-05-15 2019-04-16 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
GB2561333B (en) 2017-02-17 2020-06-03 Bo Soederpalm Treatment of alcohol use disorder
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
MX2020008704A (es) * 2018-02-23 2020-12-07 Axsome Therapeutics Inc Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro.
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US12083080B2 (en) 2023-12-04 2024-09-10 Richard Louis Price Therapeutic methods using bupropion hydrobromide
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
US3885048A (en) * 1971-02-08 1975-05-20 James J Liggett Method for preparing simulated meat, fish and dairy products
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
DK62184D0 (da) 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3485618D1 (de) 1984-08-17 1992-04-30 Wellcome Found Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung.
DE3672652D1 (de) * 1985-03-29 1990-08-23 Shinko Electric Co Ltd Eisenbahnfahrzeug mit linearmotor.
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
IT1191674B (it) 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4880622A (en) 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4837980A (en) * 1987-07-01 1989-06-13 The Uniroyal Goodrich Tire Company Method and apparatus for tire uniformity correction
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JPH02257309A (ja) * 1989-03-30 1990-10-18 Fanuc Ltd Ｎｃプログラムの描画方法
US5030457A (en) * 1989-08-28 1991-07-09 Pharmaceutical Delivery Systems, Inc. Bioerodible polymers useful for the controlled release of therapeutic agents
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
GB2245559A (en) * 1990-06-25 1992-01-08 Farmos Oy Bioceramic system for delivery of a bioactive compound.
ATE118345T1 (de) * 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
EP0636139B1 (en) * 1992-04-15 1999-11-17 Sri International Isolation of steroids containing a 5,7-diene functionality from a sterol mixture
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
EP0625069B1 (de) * 1992-10-26 1998-12-30 Schwarz Pharma Ag Verfahren zur herstellung von mikrokapseln
ATE173616T1 (de) * 1992-11-30 1998-12-15 Pfizer Verabreichungsvorrichtungen mit gestützten flüssigen membranen
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5535556A (en) * 1994-04-18 1996-07-16 Hughes, Jr.; John P. Basement wall construction
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
EP0888111B1 (en) 1996-03-08 2003-05-21 Nycomed Danmark A/S Modified release multiple-units dosage composition
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
FR2747921B1 (fr) * 1996-04-24 1998-10-30 Adir Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
SI9600330A (sl) * 1996-11-11 1998-06-30 KEKO VARICON d.o.o. Zaščitna komponenta z več funkcijami
EP0951279A1 (en) * 1997-01-10 1999-10-27 Abbott Laboratories Tablet for the controlled release of active agents
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6641614B1 (en) 1997-05-01 2003-11-04 Spinal Concepts, Inc. Multi-variable-height fusion device
US6168873B1 (en) 1997-05-29 2001-01-02 Canon Kabushiki Kaisha Electrode substrate and recording medium
ATE250929T1 (de) 1997-05-30 2003-10-15 Osmotica Corp Mehrlagige osmosevorrichtung
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
CN1256085C (zh) * 1997-07-01 2006-05-17 美国辉瑞有限公司 舍曲林盐和舍曲林的缓释剂型
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6120803A (en) 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
AU750808B2 (en) * 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US5968553A (en) 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5919484A (en) * 1998-01-15 1999-07-06 Isp Investments Inc. Controlled release, drug-delivery tableted composition including a polymer of a vinyl amide, (meth)acrylic acid, a long chain alkyl (meth)acrylate and a lower alkyl (meth)acrylate
WO1999038503A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
CA2318738A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
JP2002501890A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
ID26082A (id) 1998-03-19 2000-11-23 Briston Myers Squib Company Sistem pengiriman lepas terkendali dwifasa untuk zat-zat farmasi kelarutan tinggi dan metodenya
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
US6129931A (en) 1998-09-03 2000-10-10 Isp Investments Inc. Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone
DE69923200T2 (de) * 1998-10-01 2005-12-22 Novartis Ag Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
CA2354472C (en) * 1998-12-17 2009-02-24 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
CA2259730A1 (en) 1999-01-18 2000-07-18 Bernard Charles Sherman Sustained release tablets containing bupropion hydrochloride
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
WO2000056311A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Control of metabolism
FR2791809B1 (fr) * 1999-04-01 2001-06-15 Air Liquide Procede et dispositif de traitement d'articles stockes dans des conteneurs et appareil de stockage dote d'un tel dispositif
US6340476B1 (en) * 1999-04-06 2002-01-22 Armaquest, Inc. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US6116501A (en) 1999-04-22 2000-09-12 The Procter & Gamble Company Stackable, self-supporting container with lid-alignment feature
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
CA2324813A1 (en) 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US20040156872A1 (en) 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6541532B1 (en) * 2000-06-02 2003-04-01 Milliken & Company Scorch inhibiting compositions for polyurethane foams
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
CA2420597C (en) * 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6491947B2 (en) 2000-11-03 2002-12-10 Chemlink Laboratories, Llc Expanded perborate salt, use, and method of production
CN1352938A (zh) * 2000-11-14 2002-06-12 北京万全阳光医药科技有限公司 盐酸安非他酮缓释片
CA2685214C (en) 2001-02-08 2013-01-22 Andrx Pharmaceuticals, Inc. Improved controlled release oral dosage form
US20050031670A1 (en) 2001-05-22 2005-02-10 Jamerson Brenda Diane Weight reduction or weight controlling composition
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
DE10126163A1 (de) 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
MXPA04006163A (es) * 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
EP1465607B1 (fr) * 2002-01-09 2007-03-21 UCB Farchim S.A. Compositions pharmaceutiques a liberation modifiee
DE10200813A1 (de) 2002-01-11 2003-09-18 Krauss Maffei Kunststofftech Spritzgießmaschine mit zumindest einer Säule
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2627842T3 (es) * 2002-02-21 2017-07-31 Valeant Pharmaceuticals Luxembourg S.À.R.L. Formas de dosificación de liberación controlada
IN192747B (es) 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
KR100483588B1 (ko) * 2002-07-11 2005-04-18 주식회사 하이닉스반도체 난드형 플래시 메모리 소자의 셀렉트 라인 형성 방법
US20040115263A1 (en) * 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
MXPA05010636A (es) * 2003-04-04 2005-12-12 Pharmacia Corp Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
AR045423A1 (es) 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos

Also Published As

Publication number Publication date
EA013737B1 (ru) 2010-06-30
RS51934B (sr) 2012-02-29
ES2336913T3 (es) 2010-04-19
NO20053245D0 (no) 2005-07-01
BR0318456A (pt) 2006-09-12
EP1575565A1 (en) 2005-09-21
CN1819821A (zh) 2006-08-16
EP1575565A4 (en) 2007-05-02
EP1575565B1 (en) 2010-01-06
NZ544281A (en) 2008-07-31
HRP20050625B1 (hr) 2015-08-28
NO335271B1 (no) 2014-10-27
ATE454138T1 (de) 2010-01-15
US7537784B2 (en) 2009-05-26
ME00391B (me) 2011-10-10
BRPI0318456B8 (pt) 2021-05-25
PL196544B1 (pl) 2008-01-31
CY1109955T1 (el) 2014-09-10
HRP20050625A2 (hr) 2008-07-31
NO2015003I1 (no) 2015-02-16
PT1575565E (pt) 2010-03-03
IS7930A (is) 2005-07-01
NO20053245L (no) 2005-10-04
JP2007521231A (ja) 2007-08-02
TNSN06016A1 (en) 2007-10-03
IL171870A (en) 2011-08-31
AU2003264002A1 (en) 2005-03-07
MEP3608A (en) 2011-05-10
DK1575565T3 (da) 2010-04-12
AP1899A (en) 2008-10-10
US20060228415A1 (en) 2006-10-12
CR8056A (es) 2008-07-29
EA200600206A1 (ru) 2006-06-30
HK1083193A1 (en) 2006-06-30
WO2005016318A1 (en) 2005-02-24
PL378539A1 (pl) 2006-02-06
IS2779B (is) 2012-05-15
CA2524300A1 (en) 2005-02-24
DE60330909D1 (de) 2010-02-25
KR20060071392A (ko) 2006-06-26
CN1819821B (zh) 2010-10-13
AU2003264002B2 (en) 2010-09-02
KR101087464B1 (ko) 2011-11-25
SI1575565T1 (sl) 2010-04-30
RS20060132A (sr) 2008-06-05
BRPI0318456B1 (pt) 2021-01-05
CA2524300C (en) 2008-10-28
AP2005003463A0 (en) 2005-12-31
US20050238718A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
MXPA05012637A (es) Tableta de liberacion modificada del clorhidrato de bupropion.
DE69917866D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
AP2201A (en) Sustained-release tablet composition of pramipexole.
UA88509C2 (ru) Сублингвальная таблетка с покрытием, которое содержит опиоидный анальгетик
HUP0301887A3 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
IL166079A0 (en) Sustained-release tablet comprising reboxetine
DE60216078D1 (de) Opioid enthaltende arzneiform gegen missbrauch
DE60130328D1 (de) Vorgesteuertes entlastungsventil
ZA200410269B (en) fungicidal active substance combinations.
DE60333091D1 (de) Dynamische anrufsteuerung
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
DE60136024D1 (de) Kompositstruktur mit einer klebenden Matrix, die einen Wirkstoff oder mehr enthält
WO2007141743A3 (en) A tablet dosage form comprising cetirizine and pseudoephedrine
CO5070588A1 (es) Comprimidos de ciclofosfamida recubiertos con pelicula
ECSP056216A (es) Tableta de liberación modificada del clorhidrato de bupropion
MY145995A (en) Modified-release tablet of bupropion hydrochloride
AU2003280065A1 (en) Bupropion hydrochloride solid dosage forms
ZA200000167B (en) Sustained release tablets containing bupropion hydrochloride.
WO2005079763A3 (en) Compression-coated tablets and manufacture thereof
PL1928436T3 (pl) Układ aplikacyjny dla zawierającego substancję czynną plastra i środka do regulacji podawania tej substancji
GEP20074128B (en) Modified-release tablet of bupropion hydrochloride
NO20052680D0 (no) Forbedringsmiddel inneholdende brennstoff.
DE60013076D1 (de) Überdruckventil
MY137953A (en) New association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general